Uncategorized

jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy

by Business Wire • 2021/05/03 • 0 Comments

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy

← Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Ointment improves dry eye symptoms in meibomian gland dysfunction →

Post navigation